Shire plc (SHPG) Receives Analyst Rating

Shire plc (SHPG) : The consensus on Shire plc (SHPG) based on 12 analyst recommendation on the company stock is 1.42, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 9 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 analyst believes that the stock is a Buy, which can produce decent returns in the future. 2 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

Shire plc (SHPG) : The highest level Shire plc (SHPG) is projected to reach is $325 for the short term and the lowest estimate is at $186. The consolidated price target from 11 rating analysts who initiate coverage on the stock is $257.64 and the possibility the share price can swing is $36.47.


Also, Goldman Sachs maintains its view on Shire plc (NASDAQ:SHPG) according to the research report released by the firm to its investors. The shares have now been rated Buy by the stock experts at the ratings house. The rating by the firm was issued on June 28, 2016.

Shire plc (NASDAQ:SHPG): After opening at $193.44, the stock dipped to an intraday low of $192.8 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $196.85 and the buying power remained strong till the end. The stock closed at $196.49 for the day, a gain of 1.64% for the day session. The total traded volume was 617,251. The stocks close on the previous trading day was $193.32.

Shire plc is a biopharmaceutical company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other specialty conditions. The Company commercializes its products in the areas of Neuroscience, Gastrointestinal (GI), Rare Diseases and Other therapeutic areas. The Companys products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSE VUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), EQUASYM (methylphenidate hydrochloride) modified release (XL), BUCCOLAM, LIALDA (mesalamine)/ MEZAVANT(mesalazine), PENTASA (mesalamine), RESOLOR (prucalopride), REPLAGAL (agalsidase alfa), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), CINRYZE C1 esterase inhibitor (human), FOSRENOL (lanthanum carbonate), XAGRID/ AGRYLIN (anagrelide hydrochloride) and PLENADREN (modified release hydrocortisone).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.